ArticleBioMed research international2014
Liposomal formulation of turmerone-rich hexane fractions from Curcuma longa enhances their antileishmanial activity.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Turmeric essential oil-loaded wheat starch cryogels as superabsorbent pads for active packaging of fish fillets.Journal of the science of food and agriculture · 2026Article
- Curcumin Nanoencapsulated in Chitosan-Coated Liposomes: Therapeutic Potential against PathogenicACS omega · 2026Article
- In Vitro and In Silico Assessments of Curcuminoids and Turmerones fromPharmaceuticals (Basel, Switzerland) · 2025Article
- Pharmacological Activities of Turmerones.Current medicinal chemistry · 2025Review
- Article
- Turmeric Essential Oil Constituents as Potential Drug Candidates: A Comprehensive Overview of Their Individual Bioactivities.Molecules (Basel, Switzerland) · 2024Review
- Article
- Phytochemical Composition and Antibacterial Activity ofPlants (Basel, Switzerland) · 2023Article
- Wild Mushrooms: A Hidden Treasure of Novel Bioactive Compounds.International journal of analytical chemistry · 2023Article
- Current Applications of Plant-Based Drug Delivery Nano Systems for Leishmaniasis Treatment.Pharmaceutics · 2022Review
- Ethanolic leaf extract ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2018Article
- Development of Nanoemulsions to Enhance the Antileishmanial Activity ofBioMed research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Promastigote forms of Leishmania amazonensis were treated with different concentrations of two fractions of Curcuma longa cortex rich in turmerones and their respective liposomal formulations in order to evaluate growth inhibition and the minimal inhibitory concentration (MIC). In addition, cellular alterations of treated promastigotes were investigated under transmission and scanning electron microscopies. LipoRHIC and LipoRHIWC presented lower MIC, 5.5 and 12.5 μg/mL, when compared to nonencapsulated fractions (125 and 250 μg/mL), respectively, and to ar-turmerone (50 μg/mL). Parasite growth inhibition was demonstrated to be dose-dependent. Important morphological changes as rounded body and presence of several roles on plasmatic membrane could be seen on L. amazonensis promastigotes after treatment with subinhibitory concentration (2.75 μg/mL) of the most active LipoRHIC. In that sense, the hexane fraction from the turmeric cortex of Curcuma longa incorporated in liposomal formulation (LipoRHIC) could represent good strategy for the development of new antileishmanial agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.